References

1. Christopher R. (1996). Miracle blood lubricant: Connaught and the story of Heparin, 1928-1937. Originally published in Conntact 9: 4.

2. Gibbon JH Jr. (1937). Artificial maintenance of circulation during experimental occlusion of pulmonary artery. Arch Surg 34: 1105-1131.

3. Gibbon JH Jr. (1954). Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 37(3): 171-185.

4. Kolff WJ, Balzer RR. (1955). Artificial coil lung. Trans Am Soc Artif Int Organs 1: 39.

5. Clowes GHA Jr et al. (1956). An artificial lung dependent upon diffusion of oxygen and carbon dioxide through plastic membranes. JThorac Surg 32: 630.

6. KrautE etal. (1930). Uber die inactiviesung des Kallikreins. Hoppe-Seyler's ZPhysiol Chem 192: 1-21.

7. Kunitz M, Northrup JH. (1936). Isolation rom beef pancreas of crystalline trypsinogen, trypsin and a trypsin inhibitor and an inhibitor trypsin compound. J Gen Physiol 19: 991-1007.

8. Edmunds LH et al. (1991). Blood-surface interactions during CPB. In: Friedel N, Hetzer R, Royston D (eds.), Blood Use in Cardiac Surgery (Springer Verlag, New York).

9. Furie B, Furie BC. (1992). Molecular and cellular biology of blood coagulation. N Engl J Med 326: 800-806.

10. Rosenberg RD. (1974). Heparin action. Circulation 49: 603.

11. Coleman RW. (1984). Surface mediated defence reactions, the plasma contact activation system. J Clin Invest 73: 1249-1253.

12. Bull BS, Korpman RA, Huse WM et al. (1975). Heparin therapy during extracorporeal circulation: problems inherent in existing heparin protocols. JThorac Cardiovasc Surg 69: 674--684.

13. Akl BF, Vargas GM, NealJ et al. (1980). Clinical experience with the activated clotting time for control of heparin and protamine therapy during cardiopul-monary bypass. J Thorac Cardiovasc Surg 79: 97-102.

14. Young JA, Kisker CT, Doty DB. (1978). Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 26: 231-240.

15. Bull BS, Huse WM, Brauer FS et al. (1975). Heparin therapy during extracorpo-real circulation: the use of a drug response curve to individualise heparin and protamine dosage. JThorac Cardiovasc Surg69: 685.

16. Verska JJ. (1977). Control of heparinisation by activated clotting time during bypass with improved postoperative haemostasis. Ann Thorac Surg 24(2): 170-173.

17. DeLaval M. (1984). Personal communication.

18. Zilla P, Fasol R, Goscurth P et al. Blood platelets in cardiopulmonary bypass operations: recovery occurs after initial stimulation, rather than continual activation. J Thorac Cardiovasc Surg 97: 379-383.

19. Harker LA, Malpass TW, Branson HE et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction association with selective granule release. Blood 56: 824.

20. Edmunds LH Jr, Ellison N, Coleman RW et al. (1982). Platelet function during open heart surgery: comparison of membrane and bubble oxygenator. J Thorac Cardiovasc Surg83: 805-812.

21. Harker LA, Marzec UM, Ginsbeg MH. (1983). Thrombospondin levels in plasma, platelets, and urin in normal subjects, subjects receiving heparin, tho-racotomy patients, and patients undergoing pulmonary bypass. Thromb Haemost 50: 40.

22. Davies GC, Sobel M, Salzman EW. Elevated plasma fibrinopeptide A and Thromboxane B2 levels during cardiopulmonary bypass. Circulation 61: 808.

23. Wang JS, Lin CY, Hung WT et al. (1992). Thromboelastogram fails to predict postoperative haemorrhage in cardiac patients. Ann Thorac Surg 53: 435-439.

24. Guilmet D, BachetJ, Goudot B et al. (1989). Use of biological glue in acute aortic dissection: a new surgical technique. Preliminary clinical results. J Thorac Cardiovasc Surg 77: 516-521.

25. Fritz H, Wunderer G. (1983). Biochemistry and applications of aprotinin, the kallikrin inhibitor from bovine organs. ArzeimittelForschung 33: 479-494.

26. Orchard MA, Goodchild CS, Prentice CRM et al. (1993). Aprotinin reduces CPB induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 85: 533-541.

27. Kawasuji M, Ueyama K, Sakakibara N et al. (1993). Effect of low dose aprotinin on coagulation and fibrinolysis in CPB. Ann Thorac Surg 55: 1205-1209.

28. Marx G, Pokar H, Reuter H etal. (1991). The effects of aprotinin on haemostatic function during the cardiac surgery. J Cardiothorac Vasc Anaesth 5: 467-474.

29. Bidstrup BP, Royston D, Sapsford RN et al. (1989). Reduction in blood loss and blood use after CPB with high dose aprotinin. J Thorac Cardiovasc Surg 97: 364--372.

30. Davis R, Withington R (1995). Aprotinin: A Review of Its Pharmacology and Therapeutic Efficacy in Reducing Blood Loss Associated with Cardiac Surgery (Adis International Limited, Auckland, New Zealand), Vol. 49, No. 6, pp. 954-983.

31. Dietrich W et al. (1998). Incidence of aprotinin hypersensitivity. Ann Thorac Surg 65: 60--64.

32. Müller H, Alken A, Ziemer G et al. (1992). Aprotinin in paediatric cardiopulmonary bypass surgery. J Cardiothorac Anesth 6(Suppl 1): 100.

33. Bidstrup BP, Underwood SR, Sapsford RN. (1993). Effect of aprotinin (Trasylol) on aorto-coronary bypass graft patency. JThorac Cardiovasc Surg 105: 147-153.

34. Bouboulis N, Rivas LF, KuoJ etal. (1994). Packing of the chest: a useful technique for intractable bleeding after open heart surgery. Ann Thorac Surg 57: 856-861.

This page intentionally left blank

0 0

Post a comment